Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
7.910
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Coya Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
October 05, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
October 03, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present at the LD Micro Investor Conference
September 27, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
September 22, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases
September 07, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies
August 31, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023
August 25, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors
August 21, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
August 08, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
August 03, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
July 19, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease
July 17, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
July 05, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC)
June 28, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)
June 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs
June 14, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
June 12, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease
June 08, 2023
Via
Get News
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)
June 07, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)
June 05, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
May 22, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
May 16, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
May 10, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET
May 09, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Alzheimer’s Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer?
April 14, 2023
Via
ACCESSWIRE
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023
March 31, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results
March 29, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
March 29, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer
March 27, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
March 23, 2023
By David Willey, Benzinga
Via
TheNewswire.com
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.